487 filings
Page 5 of 25
CORRESP
9sh0 3b1yee
17 Mar 23
Correspondence with SEC
12:00am
CORRESP
wzksdy q70nt
17 Mar 23
Correspondence with SEC
12:00am
F-1/A
6nbldjkhou 6a06
13 Mar 23
Registration statement (foreign) (amended)
9:18am
CORRESP
jaeiyxqllztwv1 muwb
13 Mar 23
Correspondence with SEC
12:00am
CORRESP
uks3qo9
13 Mar 23
Correspondence with SEC
12:00am
FWP
783wgqjdruni
9 Mar 23
Free writing prospectus
4:31pm
6-K
53yuyq
9 Mar 23
Current Report
4:30pm
FWP
nn07lt8qgmdrqygzkrvv
8 Mar 23
Free writing prospectus
10:10am
F-1/A
79hiaymd lya
7 Mar 23
Registration statement (foreign) (amended)
1:02pm
F-1/A
clxk2
1 Mar 23
Registration statement (foreign) (amended)
1:02pm
F-1/A
qex3zjc
28 Feb 23
Registration statement (foreign) (amended)
4:12pm
CORRESP
lrvdkdpx2x0 14t8c3
28 Feb 23
Correspondence with SEC
12:00am
UPLOAD
b7o8 r97ibzcb9za74
24 Feb 23
Letter from SEC
12:00am
6-K
ex2pq7
17 Feb 23
Report of Foreign Private Issuer
4:30pm
F-1
aw9g99 mjbvhzaiylo2
16 Feb 23
Registration statement (foreign)
10:17am
6-K
ndiux9
27 Jan 23
Report of Foreign Private Issuer
8:50am
6-K
jx0zcr4cfd2ci
24 Jan 23
Altamira Therapeutics Provides Update on Clinical Trials with Bentrio
9:00am
SC 13D/A
ftcl q0ct0f411qpng
18 Jan 23
Altamira Therapeutics / Meyer Thomas ownership change
4:30pm
424B4
hes1qyl4889cd3bhh ae
28 Dec 22
Prospectus supplement with pricing info
9:23am
EFFECT
ccoz2cc f3m
28 Dec 22
Notice of effectiveness
12:15am